Proton Pump Inhibitors, Kidney Damage, and Mortality: An Updated Narrative Review
Advances in Therapy · 2023-06 · 40 (6) · 2693-2709
DOI: 10.1007/s12325-023-02476-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Therapy, online erschienen am 04.05.2023. Verfasst von Amber N Edinoff und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA. Hauptthemen laut MEDLINE: COVID-19, Fractures, Bone. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Since their approval by the Food and Drug Administration (FDA) in 1989, proton pump inhibitors (PPIs) have become one of the most highly utilized drugs in the United States, assuming a position as one of the top 10 most prescribed medications in the country. The purpose of PPIs is to limit the amount of gastric acid secreted by the parietal cells via irreversible inhibition of the H+/K+-ATPase pump, therefore maintaining an elevated gastric acid pH of greater than 4 for 15-21 h. Even though PPIs have many clinical uses, they are not without their adverse effects, mimicking achlorhydria. Besides electrolyte abnormalities and vitamin deficiencies, long-term use of PPIs has been linked to acute interstitial nephritis, bone fractures, poor COVID-19 infection outcomes, pneumonia, and possibly an increase in all-cause mortality. The causality between PPI use and increased mortality and disease risk can be questioned since most studies are observational. Confounding variables can greatly affect an observational study and explain the wide-ranging associations with the use of PPIs. Patients on PPIs are generally older, obese, sicker with a higher number of baseline morbidities, and on more medications than the compared PPI non-users. These findings suggest that PPI users are at a higher risk of mortality and complications based on pre-existing conditions. This narrative review aims to update readers on the concerning effects that proton pump inhibitor use can have on patients and give providers a resource to create informed decisions on appropriate PPI use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA.
- Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
- School of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
- School of Osteopathic Medicine, University of the Incarnate Word, San Antonio, USA.
- Louisiana State University Health Sciences Center at Shreveport, LSU New Orleans, Louisiana State University Health Sciences Center at Shreveport, 1501 Kings Highway, Shreveport, LA, 71130-3932, 71103, USA.
- Louisiana State University Health Sciences Center at Shreveport, LSU New Orleans, Louisiana State University Health Sciences Center at Shreveport, 1501 Kings Highway, Shreveport, LA, 71130-3932, 71103, USA. elyse.bradle…
Zitieren
APA
Edinoff, A. N., Wu, N. W., Parker, K., Dudossat, E., Linquest, L., Flanagan, C. J., Dharani, A., Patel, H., Willett, O., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2023). Proton Pump Inhibitors, Kidney Damage, and Mortality: An Updated Narrative Review. Advances in Therapy, 40(6), 2693-2709. https://doi.org/10.1007/s12325-023-02476-3
Vancouver
Edinoff AN, Wu NW, Parker K, Dudossat E, Linquest L, Flanagan CJ, et al. Proton Pump Inhibitors, Kidney Damage, and Mortality: An Updated Narrative Review. Advances in Therapy. 2023;40(6):2693-2709. doi:10.1007/s12325-023-02476-3
BibTeX
@article{Edinoff2023,
author = {Edinoff, Amber N and Wu, Natalie W and Parker, Katelyn and Dudossat, Edwin and Linquest, Lauren and Flanagan, Chelsi J and Dharani, Anam and Patel, Hirni and Willett, Olga and Cornett, Elyse M and Kaye, Adam M and Kaye, Alan D},
title = {Proton Pump Inhibitors, Kidney Damage, and Mortality: An Updated Narrative Review},
journal = {Advances in Therapy},
year = {2023},
volume = {40},
number = {6},
pages = {2693--2709},
doi = {10.1007/s12325-023-02476-3}
}
EUVIMED